Jerald Korn Net Worth

Jerald Korn biography

Jerald Korn serves as General Counsel, Corporate Secretary of the Company. Prior to joining us, Mr. Korn served in various roles at TESARO, Inc. from April 2015 to July 2019, including General Counsel and Chief Administrative Officer, Global Chief Compliance Officer and Deputy General Counsel, and Assistant General Counsel and Compliance Officer. Prior to TESARO, Mr. Korn served as Associate General Counsel at Cubist Pharmaceuticals from August 2013 to March 2015, as Deputy Chief Compliance Officer at Millennium Pharmaceuticals from July 2011 to August 2013 and as Associate General Counsel and Compliance Officer at AMAG Pharmaceuticals from August 2008 to July 2011. Prior to AMAG Pharmaceuticals, he was an associate in the law firm of Ropes & Gray LLP.

What is the salary of Jerald Korn?

As the General Counsel a Corporate Secretary of Kaleido Biosciences Inc, the total compensation of Jerald Korn at Kaleido Biosciences Inc is $1,505,420. There are no executives at Kaleido Biosciences Inc getting paid more.

How old is Jerald Korn?

Jerald Korn is 41, he's been the General Counsel a Corporate Secretary of Kaleido Biosciences Inc since 2019. There are 16 older and 1 younger executives at Kaleido Biosciences Inc. The oldest executive at Kaleido Biosciences Inc is Anne Prener, 62, who is the Independent Director.

What's Jerald Korn's mailing address?

Jerald's mailing address filed with the SEC is C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE, MA, 02139.

Insiders trading at Kaleido Biosciences Inc

Over the last 6 years, insiders at Kaleido Biosciences Inc have traded over $0 worth of Kaleido Biosciences Inc stock and bought 3,273,186 units worth $32,952,342 . The most active insiders traders include Ventures Fund Iv General Pa..., Joshua T Brumm a Ventures Fund V General Par.... On average, Kaleido Biosciences Inc executives and independent directors trade stock every 119 days with the average trade being worth of $55. The most recent stock trade was executed by Daniel L Menichella on 8 February 2021, trading 20,000 units of KLDO stock currently worth $230,000.

What does Kaleido Biosciences Inc do?

the next breakthrough microbiome company from flagship venturelabs – the innovation foundry of flagship ventures – is coming.

Kaleido Biosciences Inc executives and stock owners

Kaleido Biosciences Inc executives and other stock owners filed with the SEC include:

• Jerald Korn,
  General Counsel, Corporate Secretary
• Katharine Knobil,
  Chief Medical Officer and Head of Research and Development
• William E. Duke Jr.,
  Chief Financial Officer
• Daniel L. Menichella B.A., M.B.A.,
  Pres, CEO & Director
• Jean Mixer,
  Independent Director
• Theo Melas-Kyriazi,
  Independent Director
• Michael Bonney,
  Chairman of the Board
• Anthony Quinn,
  Independent Director
• Grady Burnett,
  Independent Director
• Bonnie Bassler,
  Independent Director
• Anne Prener,
  Independent Director
• William Duke,
  Chief Financial Officer
• Daniel Menichella,
  President, Chief Executive Officer, Principal Executive Officer
• Dr. Alison Long M.D., Ph.D.,
  Chief Medical Officer
• Dr. Mark A. Wingertzahn Ph.D.,
  Sr. VP of R&D and Head of Devel.
• Susan Stewart J.D.,
  Chief Regulatory Affairs – Advisor
• Dr. Johan Van Hylckama Vlieg Ph.D.,
  Chief Scientific Officer
• Kimberly Hocknell,
  Sr. VP of Technical Operations
• Jerald Korn J.D.,
  COO, Gen. Counsel & Corp. Sec.
• Dr. Geoffrey von Maltzahn Ph.D.,
  Co-Founder & Director
• Hylckama Vlieg Johan Van,
  Chief Scientific Officer
• Ventures Fund Iv General Pa...,
  
• Joshua T Brumm,
  See Remarks
• Alison Frances Lawton,
  See Remarks
• Maltzahn Geoffrey Von,
  Director
• Ventures Fund V General Par...,
  
• Ventures Fund Iv General Pa...,
  
• Ventures Fund Iv General Pa...,
  
• Alison S Long,
  Chief Medical Officer